Quibron T is a prescription medication specifically formulated to manage and prevent symptoms associated with reversible bronchospasm in conditions such as asthma, chronic bronchitis, and emphysema. It combines two active ingredients, theophylline and guaifenesin, to provide dual-action therapy that opens airways and facilitates mucus clearance. This makes it a cornerstone in maintenance therapy for patients requiring long-term control of obstructive airway diseases. Clinicians often recommend Quibron T for its predictable pharmacokinetics and established efficacy profile in improving pulmonary function.

Features

• Contains theophylline anhydrous 300 mg and guaifenesin 100 mg per tablet
• Extended-release formulation for sustained 12-hour dosing
• Designed to minimize peak-trough fluctuations in serum theophylline levels
• Sugar-free and dye-free composition
• Scored tablet for dose titration when medically appropriate

Benefits

• Provides prolonged bronchodilation to maintain open airways and ease breathing
• Reduces the frequency and severity of asthma attacks and bronchospastic episodes
• Helps loosen and clear bronchial secretions, improving cough productivity
• Supports consistent therapeutic drug levels for all-day and all-night symptom control
• May decrease the need for rescue inhaler use when used as prescribed
• Contributes to improved exercise tolerance and overall quality of life in respiratory patients

Common use

Quibron T is indicated for the symptomatic treatment and prophylaxis of bronchospasm associated with chronic obstructive pulmonary diseases, including asthma, chronic bronchitis, and emphysema. It is particularly useful in patients who require maintenance therapy to prevent recurrent episodes of wheezing, shortness of breath, and chest tightness. The medication is often incorporated into long-term management plans under physician supervision.

Dosage and direction

Dosage must be individualized based on patient age, weight, smoking status, and theophylline serum concentrations. The usual starting dose for adults is one tablet every 12 hours. Dosage may be adjusted in increments of no more than 100 mg theophylline per day at three-day intervals if tolerated. Tablets should be swallowed whole and not crushed or chewed. Administration with a full glass of water is recommended, and it may be taken with or without food, though consistency in timing relative to meals is advised. Serum theophylline levels should be monitored periodically, with a therapeutic range generally between 10–20 mcg/mL.

Precautions

Patients should be advised that Quibron T may cause nervousness, restlessness, or insomnia, especially when initiating therapy. Use with caution in patients with cardiovascular disorders, hypertension, hyperthyroidism, peptic ulcer disease, or seizure disorders. Elderly patients and those with hepatic impairment or congestive heart failure may have reduced theophylline clearance and require lower doses. Avoid abrupt discontinuation. Patients should be educated to recognize signs of theophylline toxicity, such as nausea, vomiting, or tachycardia.

Contraindications

Quibron T is contraindicated in individuals with known hypersensitivity to theophylline, guaifenesin, or any component of the formulation. It should not be used in patients with active peptic ulcer disease or uncontrolled seizure disorders. Concurrent use with other xanthine derivatives is not recommended.

Possible side effect

Common side effects may include nausea, vomiting, headache, insomnia, nervousness, and gastrointestinal discomfort. Less frequently, patients may experience tachycardia, palpitations, diuresis, or muscle twitching. Serious adverse effects such as seizures or cardiac arrhythmias are rare but may occur, particularly with serum levels above 20 mcg/mL.

Drug interaction

Quibron T interacts significantly with numerous medications. CYP1A2 inhibitors (e.g., cimetidine, ciprofloxacin, fluvoxamine) can increase theophylline levels, while inducers (e.g., phenytoin, rifampin, carbamazepine) may decrease levels. Concurrent use with other sympathomimetic agents may potentiate CNS stimulation. Theophylline may reduce lithium levels and enhance warfarin effects. Always review the patient’s full medication list before prescribing.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. In that case, skip the missed dose and resume the regular schedule. Doubling up on doses is not recommended due to the risk of toxicity.

Overdose

Theophylline overdose can be serious and potentially fatal. Symptoms may include severe nausea/vomiting, agitation, tremors, tachycardia, hypotension, hyperglycemia, hypokalemia, seizures, and cardiac arrhythmias. Management includes discontinuation of the drug, supportive care, and possibly activated charcoal or extracorporeal removal in severe cases. Serum theophylline levels should be obtained, and treatment is guided by concentration and clinical presentation.

Storage

Store at room temperature (15–30°C or 59–86°F) in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations and before starting or changing any medication regimen.

Reviews

Clinical studies and patient reports generally reflect satisfaction with Quibron T’s efficacy in maintaining bronchial patency and reducing exacerbation frequency when dosed appropriately. Some users note gastrointestinal side effects initially, though these often subside with continued use. Physicians appreciate its predictable release profile and utility in step-wise management of obstructive lung diseases.